(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Jason Kelce opens about wife Kylie Kelce's past pregnancy loss - 2Which Diet Prompts the Incomparable Wellbeing Results?
- 3Netflix’s Price Hikes Just Got Rejected by an Italian Court. Here’s Why It Matters Everywhere
- 4Soldiers seize power in Guinea-Bissau and detain the president
- 5Google to Use Natural Gas to Power Massive Data Center in Texas
- As tetanus vaccination rates decline, doctors worry about rising case numbers
- Peloton recalls more than 800,000 bikes after broken seat posts injure users
- Between 600 to 800 aid trucks entering Gaza daily since start of ceasefire, COGAT confirms
- Malaysia To Revive Search for Missing Flight MH370
- Is an $85 apple pie worth it? Our Thanksgiving taste test says … maybe.
- Top 10 Moving Style Architects of the Year
- Iran war upends aviation strategies
- Pick Your Favored kind of sandwich
- To fix a patient's irregular heartbeat, doctors first tested its digital 'twin'
